![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Pronóstico del mercado de tratamiento de hematuria de Asia Pacífico hasta 2028: impacto de COVID-19 y análisis regional por tratamiento (fármacos, terapias y otros), indicación (infecciones del tracto urinario, cálculos renales, uretritis, cáncer de sangre, cálculos en la vejiga, cáncer de próstata, cistitis, traumatismos) , ejercicio vigoroso, poliquistosis renal, endometriosis y menstruación), tipo (hematuria macroscópica, hematuria microscópica, hematuria idiopática y hematuria del corredor), usuario final (hospitales, clínicas y centros de cirugía ambulatoria, y otros)
Introducción al mercado
La hematuria es una afección médica en la que se encuentra presencia de sangre en la orina. . Generalmente, la orina no contiene glóbulos rojos y, por lo tanto, esto puede provocar problemas graves que también pueden causar cálculos renales, infecciones del tracto urinario y otras enfermedades hereditarias.
Además, la alta prevalencia de hematuria Se espera que las indicaciones asociadas refuercen el crecimiento del mercado durante el período previsto. Sin embargo, los casos no diagnosticados de indicaciones asociadas limitan el crecimiento del mercado de tratamiento de hematuria de Asia Pacífico.
El brote de COVID-19 ha afectado gravemente a la industria del turismo e impuso interrupciones en la cadena de suministro; Además, los países de bajos ingresos enfrentan desafíos adicionales debido a la escasez de infraestructura sanitaria. Se han adoptado medidas restrictivas en Corea del Sur, Malasia, Singapur, Filipinas y la India para prevenir la transmisión de enfermedades. Todos estos factores tuvieron un impacto moderado en el mercado del tratamiento de la hematuria durante un corto período de tiempo debido a las restricciones en la cadena de suministro y a las capacidades de fabricación limitadas. La afectación renal en pacientes con COVID -19 puede tener una amplia gama de manifestaciones, que incluyen hematuria, proteinuria, piuria y lesión renal aguda (IRA). Se ha informado que la proteinuria y la hematuria tienen una mayor prevalencia de COVID 19 que la IRA. Por otro lado, la IRA es actualmente un signo preocupante de los pacientes hospitalizados con COVID 19 y un importante factor de riesgo de muerte. Por lo tanto, el mercado del tratamiento de la hematuria se ve afectado positivamente por COVID19.
Descripción general y dinámica del mercado
Se prevé que el mercado de tratamiento de hematuria de Asia Pacífico alcance los 257,6 millones de dólares en 2028 desde los 211,0 millones de dólares de 2021; Se prevé que crezca a una tasa compuesta anual del 2,9% de 2021 a 2028. El gasto sanitario ha aumentado considerablemente debido a la creciente prevalencia de indicaciones crónicas. Los gobiernos de varias economías están invirtiendo sustancialmente en mejorar la infraestructura sanitaria. Además, los pacientes de las economías desarrolladas están tomando conciencia de los posibles tratamientos y la disponibilidad de reembolso para el tratamiento de la hematuria. La hematuria se encuentra entre los indicios iniciales de enfermedades crónicas como el cáncer de sangre, el cáncer de vejiga y el cáncer de riñón. Estas enfermedades están cubiertas por diversas pólizas de seguro médico que ayudan a facilitar el tratamiento de los pacientes y reducen la carga financiera de la atención sanitaria. Por lo tanto, mejorar el gasto sanitario y la concienciación entre los pacientes sobre el tratamiento está impulsando el mercado de tratamiento de hematuria en Asia Pacífico.
Segmentos de mercado clave
En términos de tipo, el segmento de hematuria macroscópica representó la mayor participación del mercado de tratamiento de hematuria de Asia Pacífico en 2020. En términos de tratamiento, el segmento de medicamentos representó para la mayor participación del mercado de tratamiento de hematuria de Asia Pacífico en 2020. En términos de indicación, el segmento de infecciones del tracto urinario representó la mayor participación del mercado de tratamiento de hematuria de Asia Pacífico en 2020. En términos de usuario final, el segmento de hospitales representó la mayor participación del mercado de tratamiento de hematuria de Asia Pacífico en 2020.
Principales fuentes y empresas incluidas
Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe sobre el mercado del tratamiento de la hematuria en Asia Pacífico son los sitios web de las empresas, los informes anuales, los informes financieros, los documentos del gobierno nacional y las bases de datos estadísticas, entre otros. otros. Las principales empresas que figuran en el informe son AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd y Boehringer Ingelheim International GmbH.
Informe de razones para comprar
- Comprender el panorama del mercado de tratamiento de hematuria de Asia Pacífico e identificar segmentos de mercado que probablemente garanticen un fuerte retorno
- Para comprender el panorama del mercado en constante cambio y mantenerse a la vanguardia de la competencia
- Para planificar de manera eficiente fusiones, adquisiciones y acuerdos de asociación en el mercado de tratamiento de hematuria de Asia Pacífico identificando segmentos con las ventas probables más prometedoras
- Tomar decisiones comerciales informadas a partir de un análisis perspicaz y completo de el desempeño del mercado de varios segmentos
- Para obtener una previsión de ingresos del mercado de tratamiento de hematuria de Asia Pacífico en función de varios segmentos para el período 2021-2028
SEGMENTACIÓN DEL MERCADO DE TRATAMIENTO DE HEMATURIA EN ASIA PACÍFICO
Por Tratamiento
- Fármacos
- Terapias
- Otros
Por indicación
- Infecciones del tracto urinario
- Cálculos renales
- Uretritis
- Cáncer de sangre
- Cálculos en la vejiga
- Cáncer de próstata
- Cistitis
- Trauma
- Ejercicio vigoroso
- Enfermedad renal poliquística
- Endometriosis
- Menstruación
Por Tipo
- Hematuria macroscópica
- Hematuria microscópica
- Hematuria idiopática
- Hematuria del corredor
Por usuario final
- Hospitales
- Clínicas
- Centros de cirugía ambulatoria (ASC)
- Otros
Por país
- Asia Pacífico
- China
- Japón
- India
- Corea del Sur
- Australia
- Resto de Asia Pacífico
Empresas mencionadas
- AstraZeneca
- Compañía Bristol-Myers Squibb
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- < span>Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Hematuria Treatment Market – By Treatment
1.3.2 Asia Pacific Hematuria Treatment Market – By Indication
1.3.3 Asia Pacific Hematuria Treatment Market – By Type
1.3.4 Asia Pacific Hematuria Treatment Market – By End User
1.3.5 Asia Pacific Hematuria Treatment Market – By Country
2. Asia Pacific Hematuria Treatment Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Hematuria Treatment Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific – PEST Analysis
4.3 Experts Opinion
5. Hematuria Treatment Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Hematuria-Associated Indications
5.1.2 Increasing Awareness About Treatment Options and Improving Healthcare Expenditure
5.2 Market Restraints
5.2.1 Undiagnosed Cases of Associated Indications
5.3 Market Opportunities
5.3.1 Increasing Opportunities for Related Treatments
5.4 Future Trends
5.4.1 Rise in Preference for Advanced Therapies
5.5 Impact Analysis
6. Hematuria Treatment Market – Asia Pacific Analysis
6.1 Asia Pacific Hematuria Treatment Market Revenue Forecast and Analysis
7. Hematuria Treatment Market Revenue and Forecast To 2028 – By Treatment
7.1 Overview
7.2 Asia Pacific Hematuria Treatment Market Share by Treatment 2020 & 2028 (%)
7.3 Drugs
7.3.1 Overview
7.3.2 Drugs: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Therapies
7.4.1 Overview
7.4.2 Therapies: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Others
7.5.1 Overview
7.5.2 Others: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8. Hematuria Treatment Market Revenue and Forecast To 2028 – By Indication
8.1 Overview
8.2 Asia Pacific Hematuria Treatment Market Share by Indication 2020 & 2028 (%)
8.3 Kidney Stones
8.3.1 Overview
8.3.2 Kidney Stones: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Urinary Tract Infections (UTI)
8.4.1 Overview
8.4.2 Urinary Tract Infections: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Urethritis
8.5.1 Overview
8.5.2 Urethritis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Blood Cancer
8.6.1 Overview
8.6.2 Blood Cancer: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.7 Bladder Stones
8.7.1 Overview
8.7.2 Bladder Stones: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.8 Prostate Cancer
8.8.1 Overview
8.8.2 Prostate Cancer: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.9 Cystitis
8.9.1 Overview
8.9.2 Cystitis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.10 Trauma
8.10.1 Overview
8.10.2 Trauma: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.11 Vigorous Exercise
8.11.1 Overview
8.11.2 Vigorous Exercise: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.12 Polycystic Kidney Disease
8.12.1 Overview
8.12.2 Polycystic Kidney Disease: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.13 Endometriosis
8.13.1 Overview
8.13.2 Endometriosis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.14 Menstruation
8.14.1 Overview
8.14.2 Menstruation: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
9. Hematuria Treatment Market Revenue and Forecast To 2028 – By Type
9.1 Overview
9.2 Asia Pacific Hematuria Treatment Market, By Type 2020 & 2028 (%)
9.3 Macroscopic Hematuria
9.3.1 Overview
9.3.2 Macroscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.4 Microscopic Hematuria
9.4.1 Overview
9.4.2 Microscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.5 Idiopathic Hematuria
9.5.1 Overview
9.5.2 Idiopathic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.6 Jogger’s Hematuria
9.6.1 Overview
9.6.2 Jogger’s Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
10. Hematuria Treatment Market Revenue and Forecast To 2028 – By End User
10.1 Overview
10.2 Asia Pacific Hematuria Treatment Market Share by End User 2020 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Clinics
10.4.1 Overview
10.4.2 Clinics: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.5 Ambulatory Surgical Centers (ASC’s)
10.5.1 Overview
10.5.2 Ambulatory Surgical Centers: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.6 Others
10.6.1 Overview
10.6.2 Others: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
11. Asia Pacific Hematuria Treatment Market – Geographic Analysis
11.1 Asia Pacific: Hematuria Treatment Market
11.1.1 Overview
11.1.2 Asia Pacific: Hematuria Treatment Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3 Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.4 Asia Pacific: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.5 Asia Pacific: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.6 Asia Pacific: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7 Asia Pacific: Hematuria Treatment Market, by Country, 2021 & 2028 (%)
11.1.7.1 China: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.1 China: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.2 China: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.3 China: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.1.4 China: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.1.5 China: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.2 Japan: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.1 Japan: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.2 Japan: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.3 Japan: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.2.4 Japan: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.2.5 Japan: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.3 India: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.1 India: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.2 India: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.3 India: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.3.4 India: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.3.5 India: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.4 South Korea: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.4.1 South Korea: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.4.2 South Korea: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.4.3 South Korea: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.4.4 South Korea: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.4.5 South Korea: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.5 Australia: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.5.1 Australia: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.5.2 Australia: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.5.3 Australia: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.5.4 Australia: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.5.5 Australia: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.6 Rest of Asia Pacific: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.6.1 Rest of Asia Pacific: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.6.2 Rest of Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.6.3 Rest of Asia Pacific: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.6.4 Rest of Asia Pacific: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.6.5 Rest of Asia Pacific: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
12. Impact Of COVID-19 Pandemic on Hematuria Treatment Market
12.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
13. Hematuria Treatment Market–Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 AstraZeneca
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Bristol-Myers Squibb Company
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 F. HOFFMANN-LA ROCHE LTD.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 GlaxoSmithKline Plc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Janssen Pharmaceuticals
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck & Co., Inc.
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Pfizer Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Sun Pharmaceutical Industries Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Boehringer Ingelheim International GmbH
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 2. Asia Pacific: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 3. Asia Pacific: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 4. Asia Pacific: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 5. China: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 6. China: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 7. China: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. China: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 9. Japan: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 10. Japan: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 11. Japan: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Japan: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. India: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 14. India: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 15. India: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. India: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. South Korea: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 18. South Korea: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 19. South Korea: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. South Korea: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 21. Australia: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 22. Australia: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 23. Australia: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 24. Australia: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 26. Rest of Asia Pacific: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 27. Rest of Asia Pacific: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 28. Rest of Asia Pacific: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 29. Organic Developments Done by Companies
Table 30. Inorganic Developments Done by Companies
Table 31. Glossary of Terms, Hematuria Treatment Market
LIST OF FIGURES
Figure 1. Hematuria Treatment Market Segmentation
Figure 2. Asia Pacific Hematuria Treatment Market Overview
Figure 3. Macroscopic Hematuria Segment Held the Largest Share of the Type Segment in Hematuria Treatment Market
Figure 4. India to Show Significant Growth During Forecast Period
Figure 5. Asia Pacific Hematuria Treatment Market, Industry Landscape
Figure 6. Asia Pacific PEST Analysis
Figure 7. Hematuria Treatment Market Impact Analysis of Drivers and Restraints
Figure 8. Asia Pacific Hematuria Treatment Market – Revenue Forecast and Analysis – 2020- 2028
Figure 9. Asia Pacific Hematuria Treatment Market Share by Treatment 2020 & 2028 (%)
Figure 10. Drugs: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 11. Therapies: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 12. Others: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 13. Asia Pacific Hematuria Treatment Market Share by Indication 2020 & 2028 (%)
Figure 14. Kidney Stones: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 15. Urinary Tract Infections: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 16. Urethritis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 17. Blood Cancer: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 18. Bladder Stones: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 19. Prostate Cancer: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 20. Cystitis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 21. Trauma: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 22. Vigorous Exercise: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 23. Polycystic Kidney Disease: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 24. Endometriosis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 25. Menstruation: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 26. Asia Pacific Hematuria Treatment Market, by Type 2020 & 2028 (%)
Figure 27. Macroscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 28. Microscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 29. Idiopathic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 30. Jogger’s Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 31. Asia Pacific Hematuria Treatment Market Share by End User 2020 & 2028 (%)
Figure 32. Hospitals: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 33. Clinics: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 34. Ambulatory Surgical Centers: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 35. Others: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 36. Asia Pacific: Hematuria Treatment Market, by Key Country – Revenue (2021) (US$ Million)
Figure 37. Asia Pacific: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Million)
Figure 38. Asia Pacific: Hematuria Treatment Market, by Country, 2021 & 2028 (%)
Figure 39. China: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Japan: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. India: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. South Korea: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Australia: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Rest of Asia Pacific: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Impact Of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 46. Growth Strategies Done by the Companies in the Market, (%)- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific hematuria treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific hematuria treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.